Breathing new hope: inhaled TB treatment enters human testing
NCT ID NCT07073638
Summary
This trial is testing whether an inhaled treatment called RESP30TB is safe and shows early signs of fighting tuberculosis bacteria. It involves 24 adults with newly diagnosed, drug-susceptible lung TB who will receive the treatment through a nebulizer. The main goals are to check for side effects and see if the treatment reduces bacteria in sputum during the first two weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TASK Clinical Research Centre
RECRUITINGCape Town, Bellville, 7531, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.